ProEthic transdermal ketoprofen deal

13 April 2003

The $7.3 billion global market for non-steroidal anti-inflammatorydrugs - dominated by two of the most widely prescribed medicines in the USA - may soon include an upstart competitor whose new product holds the promise of allaying joint pain but without the gastrointestinal discomfort often caused by current medications, according to a statement from ProEthic Laboratories of the USA and Applied Pharma Research, a Switzerland-based developer of innovative drug delivery systems.

They have signed a licensing agreement for a once-daily transdermal version of ketoprofen, a member of the NSAID class of drugs that also includes the popular COX-2 inhibitors Celebrex (celecoxib) from Pharmacia and Merck & Co's Vioxx (rofecoxib).

The deal with Applied Pharma gives ProEthic exclusive US marketing rights to the product. The firm will oversee clinical development in the USA, with a New Drug Application submission scheduled for late next year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight